Tenderwize
Wróć do wyszukiwania

Open-house framework agreement for Aripiprazole depot injection suspension

AOK Bayern - Die Gesundheitskasse·München, Germany·Deadline Jul 03, 2027 · 309 days left·Open·Supplies·Framework
Zarejestruj się, aby zapisaćOpen documents
Oryginalny tytuł ogłoszenia

Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Aripiprazol in der Darreichungsform Depot-Injektionssuspension, ATC N05AX12 (Kopie)

56/100

Ocena szansy

Needs reviewMedium complexity
SuppliesFrameworkOpen
Skąd ta ocena?

Szansa

56 / 100

Złożoność

48 / 100

Czynniki ryzyka

Contract documents must be submitted through the DTVP communication area, not the offer area; wrong channel could jeopa...

The last possible date for contract conclusion is 2027-07-03, and monthly start dates depend on the 3rd of the month cu...

Głęboka analiza portfolio

Głęboka analiza dopasowania firmy

Wykorzystuje:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Przegląd

Moderate opportunity

Kluczowe fakty

  • Framework procurement
  • Supplies contract
  • 1 lot
  • Duration until Aug 2027
  • Non-exclusive pharmaceutical rebate agreements for Aripiprazole depot injection suspension (ATC N05AX12).
  • Framework/open-house arrangement under § 130a(8) SGB V, with identical, non-individually negotiable contract terms.
Pokaż pełne podsumowanie

Open-house supply arrangement for Aripiprazole depot injection suspension (ATC N05AX12) in Germany, led by AOK Bayern. The model is non-exclusive and open to all pharmaceutical companies that meet the stated self-declared reliability requirement. No contract value is provided. Submission is via DTVP or by signed paper originals; the deadline for contracts starting on the next month begins on the 3rd of the previous month, and the final contract conclusion date is 2027-07-03.

Ryzyka

Contract documents must be submitted through the DTVP communication area, not the offer area; wrong channel could jeopa...

The last possible date for contract conclusion is 2027-07-03, and monthly start dates depend on the 3rd of the month cu...

Analiza może być niepełna

Przeanalizowano tylko część dokumentacji. Pozostałe dokumenty mogą zawierać dodatkowe wymagania, certyfikaty lub dokumenty do złożenia.

Kluczowe wymagania

Technical

  • The signatory's authority must be evidenced by the commercial register excerpt; otherwise a power of attorney is required.

Eligibility

  • Only pharmaceutical companies are eligible as potential contractual partners.

Administrative

  • Submit the completed and signed contract, completed and signed Annex 'Festlegung der vertragsgegenständlichen Arzneimittel', and completed and signed self-declaration on...

Zamawiający

Lokalizacja

München, DEU

Profil zamawiającego

Otwórz profil

Identyfikator

DE811695320

Działalność

Health

Części (1)

LOT-0001

Open-house framework agreement for Aripiprazole depot injection suspension

Lot 1 covers non-exclusive open-house rebate agreements for Aripiprazole in depot injection suspension form (ATC N05AX12). The notice states this is an open-house model, not a competitive open procedure, and contracts are offered on identical, non-negotiable terms to qualifying pharmaceutical companies. The lot is sourced from structured data and XML notice.

SuppliesFrameworkEU fundedElectronic submission

Lokalizacja

DE212, Germany

Czas trwania

Aug 2025 - Aug 2027

Kategoria

Pharmaceutical products

Termin

Deadline Jul 03, 2027

Szczegóły zamówienia

Data publikacji
24 Jul 2025
Języki
German

Metadane referencyjne

Podstawa prawna
32014L0024

Identyfikatory referencyjne

ID przetargu
488809-2025

Dokumenty (2)

Dokument zamówienia 1Portal składania ofert 1

Podobne przetargi

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 27 - Follitropin delta

Aug 30